Latest Regulatory Development News

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

The Australian Treasurer has issued interim directions preventing Hong Kong Ying Tak Limited from transferring or voting over 361 million shares in Northern Minerals, amid suspected breaches of foreign investment disposal orders. Northern Minerals is cooperating with regulators while focusing on its rare earths project.

EML Payments has appointed Adam Olding as its Global CEO, marking a pivotal step in its EML 2.0 transformation and signalling strengthened leadership to drive growth. Concurrently, regulatory developments around its Australian banking licence application introduce new compliance dynamics.

Champion Iron Limited has reached a key milestone by securing acceptances from over 90% of Rana Gruber shareholders for its voluntary cash offer, paving the way for full ownership and compulsory acquisition under Norwegian law.

The NSW Department of Planning and Environment has approved a six-year extension for the Dartbrook underground coal mine, pushing its operational horizon to 2033 despite ongoing financial administration challenges.

ADX Energy has released an updated assessment of its Welchau well in Austria, revealing a significant increase in prospective gas-condensate and light oil resources. The 2024 drilling results highlight promising reservoir conditions and pave the way for further appraisal.

Reef Casino Trust has issued a second supplementary target’s statement as the takeover bid by Iris Cairns Property Pty Ltd extends to August 2026 due to delayed casino licensing approvals. The board maintains its recommendation for unitholders to accept the offer, pending regulatory outcomes and expert advice.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Sequoia Financial Group has agreed with ASIC to withdraw a previously lodged Revocation Deed, signaling a regulatory shift that investors will want to watch closely.

PointsBet Holdings Limited reports a 4% revenue increase in H1 FY26 following MIXI’s acquisition of a controlling stake, with contrasting performances in Australia and Canada shaping the group’s outlook.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

Omni Bridgeway Limited reported a striking half-year performance with a 357% jump in net profit and a robust pipeline of legal finance investments. The company’s transformation into a capital-light fund manager is gaining momentum amid favourable regulatory shifts.